Foresite Capital Management Iii, LLC Aerie Pharmaceuticals Inc Transaction History

Foresite Capital Management Iii, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$12.0 - $16.13 $4.28 Million - $5.75 Million	-356,492 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$11.84 - $25.52 $23.6 Million - $50.9 Million	-1,993,985 Reduced 84.83%	356,492 $4.81 Million
Q3 2019 Nov 13, 2019	BUY	$18.41 - $28.0 $7.36 Million - $11.2 Million	400,000 Added 20.51%	2,350,477 $45.2 Million
Q4 2018 Feb 13, 2019	BUY	$33.0 - $60.04 $8 Million - $14.6 Million	242,431 Added 14.19%	1,950,477 $70.4 Million
Q2 2018 Aug 14, 2018	SELL	$47.85 - $70.45 $11.6 Million - $17.1 Million	-242,431 Reduced 12.43%	1,708,046 $115 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,950,477	1,950,477 $102 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iii, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Iii, LLC with notifications on news.